A Phase 3 interventional study of Intravitreal injection of Bevacizumab in Age Related Macular Degeneration and Choroidal Neovascularization, sponsored by Asociación para Evitar la Ceguera en México. Terminated at 1 site in Mexico. Open to participants aged 60 Years to 95 Years. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Asociación para Evitar la Ceguera en México · Phase 3, Interventional, and Treatment
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 20 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Asociación para Evitar la Ceguera en México is the lead sponsor of 60 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Any visual acuity
Exclusion Criteria:
* Basal Inflammatory disease
Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Asociación para Evitar la Ceguera en México